A61K 38/2278
Vasoactive intestinal peptide [vip]
Official title: {Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)}
A61K38/2278 (Vasoactive intestinal peptide [vip]) appears on 228 US grants and 422 published applications in this corpus.
Search patents in A61K- Granted patents
- 228
- Published applications
- 422
- Assignees
- 164
- Inventors
- 639
- Latest grant
- 24 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 1 | 0 |
| 1998 | 4 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 0 |
| 2002 | 3 | 8 |
| 2003 | 3 | 8 |
| 2004 | 4 | 21 |
| 2005 | 7 | 13 |
| 2006 | 3 | 21 |
| 2007 | 7 | 11 |
| 2008 | 8 | 20 |
| 2009 | 8 | 22 |
| 2010 | 2 | 15 |
| 2011 | 8 | 18 |
| 2012 | 11 | 14 |
| 2013 | 13 | 29 |
| 2014 | 13 | 23 |
| 2015 | 12 | 29 |
| 2016 | 15 | 28 |
| 2017 | 18 | 13 |
| 2018 | 14 | 20 |
| 2019 | 3 | 14 |
| 2020 | 15 | 16 |
| 2021 | 11 | 15 |
| 2022 | 10 | 16 |
| 2023 | 7 | 17 |
| 2024 | 10 | 15 |
| 2025 | 7 | 12 |
| 2026 | 2 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Implantable medical devices for extended release of therapeutic agents24 Mar 2026US 12,582,607 B2Nano Precision Medical, Inc.
- Insulin preparations containing methionine24 Feb 2026US 12,558,307 B2Sanofi-Aventis
- Controlled release formulations for the induction and proliferation of blood cells9 Dec 2025US 12,491,159 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Vasoactive intestinal peptide release from microparticles26 Aug 2025US 12,397,041 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof24 Jun 2025US 12,337,028 B2The Scripps Research Institute
- Combination treatments to promote epithelial integrity and treat ocular disorders1 Oct 2026US 2026/0295013 A1Wayne State University
- Long-Acting Formulations of Insulin28 May 2026US 2026/0144850 A1Sanofi
- Compositions for drug administration12 Feb 2026US 2026/0041775 A1Aegis Therapeutics, LLC
- Vasoactive lntestinal Peptide Release From Microparticles15 Jan 2026US 2026/0014231 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof4 Dec 2025US 2025/0367259 A1The Scripps Research Institute
Most cited
By later US patents
- Chronic treatment regimen using glucagon-like insulinotropic peptides139US 7,259,233 B2Eli Lilly and Company · 2007
- Exendin agonist formulations and methods of administration thereof133US 6,902,744 B1Amylin Pharmaceuticals, Inc. · 2005
- Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus114US 6,506,724 B1Amylin Pharmaceuticals, Inc. · 2003
- Polypeptide compositions with improved stability111US 7,022,674 B2Eli Lilly and Company · 2006
- Inotropic and diuretic effects of exendin and GLP-1109US 6,703,359 B1Amylin Pharmaceuticals, Inc. · 2004